First in Men Study: BIOMAG-I

2019-11-14 17:39:54 | BioPortfolio


A prospective, multi-center, first-in-man trial. Up to 115 subjects will be enrolled.


Clinical follow-up visits will take place at 1, 6, and 12 months and annually thereafter until 36 months post procedure.

All subjects will undergo an angiographic follow-up at 6- and 12-month follow up.

IVUS, (including IVUS-VH documentation) and OCT will be performed for all subjects at 6-month and 12-month follow-up (if the safety of the subject allows it and as per the investigator's decision).

Vasomotion will be assessed angiographically with Acetylcholine followed by Nitroglycerine at 12 months follow up in a subgroup of subjects, upon the investigators discretion and if subject consents.

Study Design


Coronary Artery Disease


Implantation of a Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold


Medizinische Universität Graz


Not yet recruiting


Biotronik AG

Results (where available)

View Results


Published on BioPortfolio: 2019-11-14T17:39:54-0500

Clinical Trials [4682 Associated Clinical Trials listed on BioPortfolio]

Safety and Clinical Performance of a Sirolimus-eluting Absorbable Metal Scaffold

Assessment of the clinical performance and the safety of the Magmaris Sirolimus-Eluting Resorbable Coronary Magnesium Scaffold in a cohort of patients in India with de novo coronary artery...

OCT Guided Magmaris RMS in STEMI

Percutaneous treatment of coronary artery disease depends on the implantation of stents within diseased coronary segments. Compared with conventional bare-metal and drug- eluting stents, w...

A First-in-Man Study to Evaluate the Feasibility and Safety of Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System

The study is a pilot clinical trial for Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System(IBS). The main purpose of this study is to evaluate the feasibility, preliminary s...

A First-in-Man Study of IBS

The study is a pilot clinical trial for Sirolimus-eluting Iron Bioresorbable Coronary Scaffold System(IBS). The main purpose of this study is to evaluate the feasibility, preliminary s...

Safety & Performance Study of the FANTOM Sirolimus-Eluting Bioresorbable Coronary Scaffold

The FANTOM II trial is intended to assess safety and performance of the Fantom Bioresorbable Coronary Scaffold in native coronary arteries.

PubMed Articles [3769 Associated PubMed Articles listed on BioPortfolio]

Sirolimus-Eluting Magnesium Resorbable Scaffold Implantation in Patients with Acute Myocardial Infarction.

To date, very little is known about the performance of a sirolimus-eluting bioresorbable magnesium scaffold (Mg-BRS) in patients with acute myocardial infarction (AMI). A multicenter cohort analysis w...

Safety and effectiveness of the self-aPposing, bAlloon-delivered, siRolimus-eluting stent for the Treatment of the coronary Artery disease: SPARTA, a multicenter experience.

To assess the long-term outcomes of patients treated with sirolimus-eluting Stentys stent in a real-life setting.

Second generation, sirolimus-eluting, bioresorbable Tyrocore scaffold implantation in patients with ST-segment elevation myocardial infarction: Baseline OCT and 30-day clinical outcomes - A FANTOM STEMI pilot study.

There is paucity of data on acute performance of Fantom (REVA Medical, CA), a second generation sirolimus-eluting bioresorbable scaffold (BRS), in ST-segment elevation myocardial infarction (STEMI) pa...

First-in-man randomized comparison of the Angiolite® durable fluoro-acrylate polymer-based sirolimus-eluting stent versus durable fluoropolymer-based everolimus eluting stent in patients with coronary artery disease: The ANGIOLITE trial.

The durable fluoro-acrylate polymer-based sirolimus-eluting stent (Angiolite®SES) has shown promising preclinical and clinical results regarding inflammatory vascular reaction and neointimal healing....

Coronary Artery Aneurysm after Second-Generation Drug-Eluting Stent Implantation.

We evaluated the incidence, predictors, and prognosis of coronary artery aneurysm (CAA) after second-generation drug-eluting stent (DES) implantation.

Medical and Biotech [MESH] Definitions

Abnormal balloon- or sac-like dilatation in the wall of CORONARY VESSELS. Most coronary aneurysms are due to CORONARY ATHEROSCLEROSIS, and the rest are due to inflammatory diseases, such as KAWASAKI DISEASE.

Malformations of CORONARY VESSELS, either arteries or veins. Included are anomalous origins of coronary arteries; ARTERIOVENOUS FISTULA; CORONARY ANEURYSM; MYOCARDIAL BRIDGING; and others.

Complete blockage of blood flow through one of the CORONARY ARTERIES, usually from CORONARY ATHEROSCLEROSIS.

Direct myocardial revascularization in which the internal mammary artery is anastomosed to the right coronary artery, circumflex artery, or anterior descending coronary artery. The internal mammary artery is the most frequent choice, especially for a single graft, for coronary artery bypass surgery.

Surgical therapy of ischemic coronary artery disease achieved by grafting a section of saphenous vein, internal mammary artery, or other substitute between the aorta and the obstructed coronary artery distal to the obstructive lesion.

More From BioPortfolio on "First in Men Study: BIOMAG-I"

Quick Search

Searches Linking to this Trial